ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Roche and Halozyme Therapeutics have signed an agreement to apply Halozyme's Enhanze drug delivery technology to Roche's biological therapeutic compounds. Enhanze is based on recombinant human hyaluronidase, an analog of a human enzyme that temporarily clears space in the matrix of tissues such as skin. The Roche Venture Fund will invest $11 million in Halozyme. Moreover, Roche will pay Halozyme $20 million up front and possibly make milestone and other payments. Separately, Roche has formed a partnership with Vancouver-based Xenon to develop protein therapeutics targeting hemojuvelin as a novel approach to treating a form of anemia. The Roche Venture Fund will invest $7 million in Xenon, and Roche itself could make $44 million in milestone payments to the firm.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X